A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic.
A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic.
Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.
